Document 0652
 DOCN  M9590652
 TI    KS update. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003.
       800-458-5231 ext. 5023.
 DT    9509
 SO    Notes Undergr. 1995 Winter;(no 29):4. Unique Identifier : AIDSLINE
       AIDS/95700303
 AB    The Food and Drug Administration (FDA) has recently granted accelerated
       approval to Liposome Technology, Inc., to market DOX-SL for people with
       AIDS with refractory Kaposi's sarcoma (KS). DOX-SL, an intravenous drug,
       is a new form of a regular cancer chemotherapy called doxorubicin, and
       has dosing schedules similar to standard chemotherapy. The drug,
       encapsulated in lipid membranes (liposomes), will enable doxorubicin to
       be delivered directly in a higher concentration to KS lesions, with
       fewer systemic side effects. The drug will likely be used in combination
       with standard chemotherapy. Side effects include: hair loss, nausea, and
       neutropenia. This is the first time the FDA has ever approved a drug for
       KS.
 DE    Doxorubicin/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC  USE
       Drug Approval  Drug Carriers  Human  Infusions, Intravenous  Liposomes
       Sarcoma, Kaposi's/*DRUG THERAPY  NEWSLETTER ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).